ALS - Xconomy

by in

Entry	Author	Date	Location
Biogen Idec’s ALS Drug Fails Phase III Trial	Catherine Arnst	01/03/13	Boston
Tantalizing Hints of Progress Against ALS for Cytokinetics, Others	Bernadette Tansey	11/14/12	San Francisco
Xconomist of the Week: Tom Maniatis on Prize4Life and ALS Research	Arlene Weintraub	05/17/12	National
Biogen Idec Buys Drug Rights from Neurimmune for $32.5M	Ryan McBride	12/21/10	Boston
Life Wants Ion Torrent for Fast Gene Sequencing, Biogen-Idec Takes On Lou Gehrig’s Disease, Two Biotechs Move Toward IPOs, & More San Diego Life Science News	Bruce V. Bigelow	08/19/10	San Diego
Biogen Idec Strikes Potential $345M Deal with Knopp to Develop ALS Drug	Ryan McBride	08/18/10	Boston
PatientsLikeMe Growing as Pharma Customers Boost Focus on Patients	Ryan McBride	02/10/10	Boston
San Diego Inventor’s Drug Discovery is Nothing to Laugh (or Cry) About	Denise Gellene	09/04/09	San Diego
Isis Prepares Novel Treatment for Lou Gehrig’s Disease, BrainCells Is Encouraged by New Drug for Depression, Inovio Raises $30M, & More San Diego Life Sciences News	Bruce V. Bigelow	08/06/09	San Diego
Isis, Genzyme Use Antisense to Go Where Many Drugs Fail—The Brain	Luke Timmerman	08/05/09	San Diego
No More Tears: Avanir Investors Await Trial Results on Emotional Outburst Drug	Denise Gellene	07/23/09	San Diego
Link Medicine Raises $40 Million to Counter Neurodegenerative Disease	Wade Roush	09/30/08	Boston
Page 1 of 1

Xconomy National